Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Blood (2018) 132 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2018-99-115340

Published: 2018

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Polycythemia Vera or Essential Thrombocythemia Transformed to Myelofibrosis or Acute Myeloid Leukemia: a Single Center Experience

Paolo Bernasconi, Anna Amelia Colombo, MD, Daniela Caldera, MD, Virginia Valeria Ferretti, Silvia Mangiacavalli, MD, Marta Ubezio, MD, Daniela Pietra, PhD, Elisa Rumi, MD, Ilaria Carola Casetti, MD, Matteo Davià, Marina Boni, Irene Dambruoso, Rita Zappatore

Blood (2017) 130 (Supplement 1): 5497.

https://doi.org/10.1182/blood.V130.Suppl_1.5497.5497

Published: 2017

Journal Articles

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Giovanni Palladini, MDPhD, Marco Basset, MD, Paolo Milani, MD, Marzia Varettoni, MD, Silvia Mangiacavalli, MD, Francesca Russo, MD, Andrea Foli, MD, Alessandro Corso, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 1760.

https://doi.org/10.1182/blood.V130.Suppl_1.1760.1760

Published: 2017

Journal Articles

VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials

Federica Cocito, MD, Silvia Mangiacavalli, MD, Virginia Valeria Ferretti, PhD, Claudio Salvatore Cartia, MD, Maya Ganzetti, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2016) 128 (22): 5711.

https://doi.org/10.1182/blood.V128.22.5711.5711

Published: 2016

Journal Articles

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Silvia Mangiacavalli, MD, Federica Cocito, MD, Virginia Valeria Ferretti, PhD, Claudio Salvatore Cartia, MD, Maya Ganzetti, MD, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2016) 128 (22): 5695.

https://doi.org/10.1182/blood.V128.22.5695.5695

Published: 2016

Journal Articles

Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

Blood (2016) 128 (22): 4494.

https://doi.org/10.1182/blood.V128.22.4494.4494

Published: 2016

Journal Articles

Confocal Microscopy Is Useful for Detection of Bortezomib Related Neuropathy (BOR-PN) in Multiple Myeloma (MM) Patients (PTS)

Federica Cocito, MD, Silvia Mangiacavalli, MD, Gabriella Ricciardelli, MD, Virginia Ferretti, PhD, Roberto Ceccuzzi, MD, Mario Cazzola, MD, paolo Emilio Bianchi, MD, Alessandro Corso

Blood (2014) 124 (21): 5691.

https://doi.org/10.1182/blood.V124.21.5691.5691

Published: 2014

Journal Articles

High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents

Silvia Mangiacavalli, MD, Alessandra Pompa, MD, Cristiana Pascutto, PhD, Virginia Ferretti, DR, Lara Pochintesta, MD, Federica Cocito, MD, Marzia Varettoni, Mario Lazzarino, Prof, Mario Cazzola, MD, Alessandro Corso, MD

Blood (2013) 122 (21): 1896.

https://doi.org/10.1182/blood.V122.21.1896.1896

Published: 2013

Journal Articles

Serum C-Terminal Telopeptide Maintains Its Correlation with Bone Disease in Myeloma Patients Even Under Treatment with Bisphosphonates

Lara Pochintesta, Silvia Mangiacavalli, MD, Federica Cocito, MD, Cristiana Pascutto, Alessandra Pompa, Mario Cazzola, Alessandro Corso

Blood (2012) 120 (21): 4003.

https://doi.org/10.1182/blood.V120.21.4003.4003

Published: 2012

Journal Articles

Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS

Alessandro Corso, MD, Silvia Mangiacavalli, MD, Federica Cocito, MD, Cristiana Pascutto, Cesare Astori, MD, Marzia Varettoni, MD, Ester Orlandi, MD, Patrizia Zappasodi, MD, Silvia Rizzi, MD, Ilaria Ambaglio, MD, Mario Lazzarino, Prof, Mario Cazzola, MD

Blood (2010) 116 (21): 3037.

https://doi.org/10.1182/blood.V116.21.3037.3037

Published: 2010

Journal Articles

Immunoglobulin Heavy Chain (IGH) Gene Rearrangement In Waldenström Macroglobulinemia and Other Monoclonal IgM Disorders

Marzia Varettoni, Silvia Zibellini, Luca Arcaini, Ester Orlandi, Cristiana Pascutto, Emanuela Boveri, Alessandro Corso, Francesco Passamonti, Silvia Mangiacavalli, MD, Silvia Rizzi, Lara Pochintesta, Marco Paulli, Enrica Morra, Mario Lazzarino

Blood (2010) 116 (21): 4139.

https://doi.org/10.1182/blood.V116.21.4139.4139

Published: 2010

Journal Articles

Has the Incidence of Extramedullary Disease Changed with the New Therapeutic Approaches? Analysis of a Cohort of 965 Multiple Myeloma (MM) Patients (pts).

Marzia Varettoni, MD, Alessandro Corso, MD, Gianmatteo Pica, MD, Patrizia Zappasodi, MD, Silvia Mangiacavalli, MD, Cristiana Pascutto, Mario Lazzarino

Blood (2007) 110 (11): 4749.

https://doi.org/10.1182/blood.V110.11.4749.4749

Published: 2007

Journal Articles

Low Efficacy of Thalidomide in Improving Response after Induction in Myeloma Patients Candidate to High-Dose Therapy.

Alessandro Corso, MD, Silvia Mangiacavalli, MD, Luciana Barbarano, MD, Patrizia Zappasodi, MD, Luciano Banfi, MD, Luigi Montalbetti, MD, Antonio Mazzone, MD, Sergio Fava, MD, Guido Frigerio, MD, Luciano Isa, MD, Sergio Montanara, MD, Daniele Perego, MD, Maria Savarè, MD, Lilj Uziel, MD, Alessandro Vismara, MD, Leonardo Campiotti, MD, Mario Fiumanò, MD, Mario Lazzarino, MD, Enrica Morra, MD

Blood (2006) 108 (11): 3567.

https://doi.org/10.1182/blood.V108.11.3567.3567

Published: 2006

Journal Articles

Bisphosphonates and Osteonecrosis of the Jaw: Advantages of a New Schedule.

Patrizia Zappasodi, MD, Alessandro Corso, MD, Marzia Varettoni, MD, Catherine Klersy, MD, Gianmatteo Pica, MD, Silvia Mangiacavalli, MD, Mario Lazzarino, MD

Blood (2006) 108 (11): 3590.

https://doi.org/10.1182/blood.V108.11.3590.3590

Published: 2006

Journal Articles

Modification of Cytokine Levels and CD34+ Stem Cell Adhesion Molecules during Mobilization in Multiple Myeloma (MM) Patients.

Patrizia Zappasodi, MD, Alessandro Corso, MD, Chiara Rusconi, MD, Mara De Amici, Erica Consensi, Cristiana Pascutto, Marzia Varettoni, MD, Silvia Mangiacavalli, MD, Gianmatteo Pica, MD, Mario Lazzarino, MD

Blood (2005) 106 (11): 5068.

https://doi.org/10.1182/blood.V106.11.5068.5068

Published: 2005

NARROW

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Polycythemia Vera or Essential Thrombocythemia Transformed to Myelofibrosis or Acute Myeloid Leukemia: a Single Center Experience

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials

Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration

Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

Confocal Microscopy Is Useful for Detection of Bortezomib Related Neuropathy (BOR-PN) in Multiple Myeloma (MM) Patients (PTS)

High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents

Serum C-Terminal Telopeptide Maintains Its Correlation with Bone Disease in Myeloma Patients Even Under Treatment with Bisphosphonates

Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS

Immunoglobulin Heavy Chain (IGH) Gene Rearrangement In Waldenström Macroglobulinemia and Other Monoclonal IgM Disorders

Has the Incidence of Extramedullary Disease Changed with the New Therapeutic Approaches? Analysis of a Cohort of 965 Multiple Myeloma (MM) Patients (pts).

Low Efficacy of Thalidomide in Improving Response after Induction in Myeloma Patients Candidate to High-Dose Therapy.

Bisphosphonates and Osteonecrosis of the Jaw: Advantages of a New Schedule.

Modification of Cytokine Levels and CD34+ Stem Cell Adhesion Molecules during Mobilization in Multiple Myeloma (MM) Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only